|
JUP |
junction plakoglobin |
- Adherens junctions interactions
- VEGFR2 mediated vascular permeability
- Neutrophil degranulation
- Keratinization
- Formation of the cornified envelope
|
|
- Arrhythmogenic right ventricular cardiomyopathy (ARVC)
- Naxos disease and Carvajal syndrome
|
|
LACTB |
lactamase beta |
|
|
|
|
LCK |
LCK proto-oncogene, Src family tyrosine kinase |
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Signaling by SCF-KIT
- Signaling by SCF-KIT
- Regulation of KIT signaling
- Nef and signal transduction
- Nef Mediated CD4 Down-regulation
- Downstream TCR signaling
- Phosphorylation of CD3 and TCR zeta chains
- Translocation of ZAP-70 to Immunological synapse
- Generation of second messenger molecules
- PECAM1 interactions
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- DAP12 signaling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- CD28 dependent Vav1 pathway
- CTLA4 inhibitory signaling
- PD-1 signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Interleukin-2 signaling
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- FLT3 signaling through SRC family kinases
|
- Dasatinib
- AP-22408
- Staurosporine
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- {4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid
- Phosphoaminophosphonic Acid-Adenylate Ester
- 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
- 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE
- 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE
- N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
- N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
- N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine
- Ponatinib
- Nintedanib
- Fostamatinib
- Zanubrutinib
|
- Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
|
|
LDHA |
lactate dehydrogenase A |
|
- NADH
- Etheno-NAD
- Nicotinamide
- Oxamic Acid
- Stiripentol
- Copper
- Artenimol
|
|
|
LDHB |
lactate dehydrogenase B |
|
- NADH
- 4-Hydroxy-1,2,5-oxadiazole-3-carboxylic acid
- Oxamic Acid
- Stiripentol
- Artenimol
|
|
|
NCAN |
neurocan |
- A tetrasaccharide linker sequence is required for GAG synthesis
- Chondroitin sulfate biosynthesis
- Dermatan sulfate biosynthesis
- CS/DS degradation
- ECM proteoglycans
- Defective B4GALT7 causes EDS, progeroid type
- Defective B3GAT3 causes JDSSDHD
- Defective CHST3 causes SEDCJD
- Defective CHST14 causes EDS, musculocontractural type
- Defective CHSY1 causes TPBS
- L1CAM interactions
- NCAM1 interactions
- Defective B3GALT6 causes EDSP2 and SEMDJL1
|
- Beta-D-Glucose
- Thiodigalactoside
- Hyaluronic acid
|
|
|
NID1 |
nidogen 1 |
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Laminin interactions
- Laminin interactions
|
|
|
|
PPFIA1 |
PTPRF interacting protein alpha 1 |
- Serotonin Neurotransmitter Release Cycle
- Norepinephrine Neurotransmitter Release Cycle
- Glutamate Neurotransmitter Release Cycle
- Dopamine Neurotransmitter Release Cycle
- Acetylcholine Neurotransmitter Release Cycle
- Receptor-type tyrosine-protein phosphatases
|
|
|
|
PPFIA2 |
PTPRF interacting protein alpha 2 |
- Serotonin Neurotransmitter Release Cycle
- Norepinephrine Neurotransmitter Release Cycle
- Glutamate Neurotransmitter Release Cycle
- Dopamine Neurotransmitter Release Cycle
- Acetylcholine Neurotransmitter Release Cycle
- Receptor-type tyrosine-protein phosphatases
|
|
|
|
PPFIA3 |
PTPRF interacting protein alpha 3 |
- Serotonin Neurotransmitter Release Cycle
- Norepinephrine Neurotransmitter Release Cycle
- Glutamate Neurotransmitter Release Cycle
- Dopamine Neurotransmitter Release Cycle
- Acetylcholine Neurotransmitter Release Cycle
- Receptor-type tyrosine-protein phosphatases
|
|
|
|
PRPF40A |
pre-mRNA processing factor 40 homolog A |
- mRNA Splicing - Major Pathway
|
|
|
|
PTPRA |
protein tyrosine phosphatase receptor type A |
- NCAM signaling for neurite out-growth
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
|
|
|
|
PTPRD |
protein tyrosine phosphatase receptor type D |
- Receptor-type tyrosine-protein phosphatases
- Synaptic adhesion-like molecules
|
|
|
|
PTPRZ1 |
protein tyrosine phosphatase receptor type Z1 |
- Other interleukin signaling
|
|
|
|
RAP1GDS1 |
Rap1 GTPase-GDP dissociation stimulator 1 |
|
|
|
|
RET |
ret proto-oncogene |
- RAF/MAP kinase cascade
- RET signaling
|
- Sorafenib
- 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- Vandetanib
- Cabozantinib
- Regorafenib
- Ponatinib
- Lenvatinib
- Fostamatinib
- Amuvatinib
- Selpercatinib
- Pralsetinib
|
- Hirschsprung disease (HD)
- Renal agenesis and Renal adysplasia
- Thyroid cancer
- Congenital central hypoventilation syndrome (CCHS)
|
|
RHOA |
ras homolog family member A |
- GPVI-mediated activation cascade
- Axonal growth inhibition (RHOA activation)
- Rho GTPase cycle
- PI3K/AKT activation
- Axonal growth stimulation
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- G beta:gamma signalling through PI3Kgamma
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- EPHA-mediated growth cone collapse
- EPHA-mediated growth cone collapse
- PCP/CE pathway
- G alpha (12/13) signalling events
- Sema4D mediated inhibition of cell attachment and migration
- Sema4D induced cell migration and growth-cone collapse
- Sema4D induced cell migration and growth-cone collapse
- VEGFA-VEGFR2 Pathway
- RHO GTPases activate PKNs
- RHO GTPases activate CIT
- RHO GTPases activate CIT
- RHO GTPases activate KTN1
- RHO GTPases Activate ROCKs
- RHO GTPases Activate ROCKs
- RHO GTPases Activate Formins
- RHO GTPases Activate Rhotekin and Rhophilins
- RHO GTPases Activate Rhotekin and Rhophilins
- Ovarian tumor domain proteases
- ERBB2 Regulates Cell Motility
- Neutrophil degranulation
- PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
- SLIT2:ROBO1 increases RHOA activity
|
|
|
|
ROCK2 |
Rho associated coiled-coil containing protein kinase 2 |
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- EPHA-mediated growth cone collapse
- G alpha (12/13) signalling events
- Sema4D induced cell migration and growth-cone collapse
- Sema4D induced cell migration and growth-cone collapse
- VEGFA-VEGFR2 Pathway
- RHO GTPases Activate ROCKs
- RHO GTPases Activate ROCKs
- RHOBTB1 GTPase cycle
- Potential therapeutics for SARS
|
- Fasudil
- Y-27632
- Fostamatinib
- Ripasudil
- Netarsudil
|
|
|
SEMG1 |
semenogelin 1 |
- Antimicrobial peptides
- Amyloid fiber formation
|
- Zinc
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
|
|
SEMG2 |
semenogelin 2 |
|
- Zinc chloride
- Zinc sulfate, unspecified form
|
|